Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.04. | Enliven Therapeutics files to sell 6.43M shares for holders | 1 | Seeking Alpha | ||
16.04. | Risk adjusted net present value: What is the current valuation of Enliven Therapeutics's ELVN-002? | 2 | Pharmaceutical Technology | ||
11.04. | Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program | 2 | Benzinga.com | ||
11.04. | Enliven Therapeutics jumps after cancer drug shows promise in early trial | 1 | Reuters | ||
11.04. | Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday | 4 | Benzinga.com | ||
11.04. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia | 68 | GlobeNewswire (Europe) | Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative... ► Artikel lesen | |
09.04. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.04. | Enliven Therapeutics, Inc.: Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors | 1 | GlobeNewswire (USA) | ||
09.04. | Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says | 1 | Benzinga.com | ||
28.03. | Enliven Therapeutics, Inc.: Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 | 53 | GlobeNewswire (Europe) | BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development... ► Artikel lesen | |
23.03. | Enliven Therapeutics director sells over $250k in stock | 3 | Investing.com | ||
21.03. | Enliven Therapeutics director sells $18.4k in company stock | 1 | Investing.com | ||
19.03. | Enliven Therapeutics announces $90M private placement to fund R&D activities | 4 | Seeking Alpha | ||
19.03. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates | 472 | GlobeNewswire (Europe) | Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026... ► Artikel lesen | |
14.03. | Enliven Therapeutics GAAP EPS of -$0.47 | 1 | Seeking Alpha | ||
14.03. | Enliven Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
14.03. | Enliven Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
14.03. | Enliven Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
14.03. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.03. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update | 57 | GlobeNewswire (Europe) | Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024 IND application to evaluate ELVN-002 in... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MORPHOSYS | 66,20 | +0,84 % | ÜBERNAHME-FIEBER bei Biotech-Aktien! Evotec, Bayer, Vidac Pharma - wer folgt auf Morphosys? | Im Biotech-Sektor herrscht Übernahme-Fieber. Zuletzt hat Genmab den Kauf von ProfoundBio, das US-Biotech-Unternehmen entwickelt Medikamente gegen Eierstock- und Gebärmutterschleimhautkrebs, für 1,8... ► Artikel lesen | |
VALNEVA | 3,400 | -1,96 % | Valneva Aktie: Unsicherheit und Analyse | Die Valneva-Aktie notiert aktuell bei 3,54 € und verzeichnet eine Veränderung von 1,32% im Vergleich zur Vorwoche. Diese Entwicklung verdeutlicht die derzeitige Unsicherheit am Markt: Trotz des vorherrschenden... ► Artikel lesen | |
EPIGENOMICS | 1,535 | -5,25 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
BIOFRONTERA | 0,330 | -13,16 % | PTA-NVR: Biofrontera AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG | DJ PTA-NVR: Biofrontera AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG
Gesamtstimmrechte gemäß § 41 WpHG
Leverkusen (pta/23.04.2024/19:57) - 1. Emittent Biofrontera AG,... ► Artikel lesen | |
CRISPR THERAPEUTICS | 49,500 | -2,94 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.03.2024 - 4 | The following instruments on Boerse Frankfurt do have their last trading day on 14.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.03.2024ISIN NameCH0305285295 VARIA... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,866 | +0,70 % | EQS-News: Defence Therapeutics Inc.: Der AccuTOX ARM-002-Impfstoff zur Krebsbekämpfung führt zu einer hochwirksamen Antigenpräsentation | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
DER ACCUTOX ARM-002-IMPFSTOFF ZUR KREBSBEKÄMPFUNG FÜHRT ZU EINER HOCHWIRKSAMEN ANTIGENPRÄSENTATION... ► Artikel lesen | |
BLUEBIRD BIO | 0,829 | -3,92 % | bluebird bio receives non-compliance notice from Nasdaq | ||
AFFIMED | 4,780 | -5,91 % | Affimed N.V.: Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology | The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted... ► Artikel lesen | |
SORRENTO THERAPEUTICS | 0,220 | 0,00 % | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento Therapeutics to its Stockholders as a Dividend | PALO ALTO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid... ► Artikel lesen | |
GINKGO BIOWORKS | 0,924 | -6,67 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
DENALI THERAPEUTICS | 14,510 | -0,41 % | Biotech-Hoffnung Denali explodiert 38 Prozent: So sind Sie jetzt bei den Top-Trends der Branche ... | Mit einem Kursplus von 38 Prozent hat sich die Aktie des Biotech-Unternehmens Denali Therapeutics am Dienstag eindrucksvoll zurückgemeldet. Der Grund für den Kurssprung sind allerdings nicht Studiendaten... ► Artikel lesen | |
FATE THERAPEUTICS | 3,790 | +0,45 % | Fate Therapeutics, Inc.: Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting | Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory... ► Artikel lesen | |
CELLECTIS | 2,415 | +0,42 % | Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 | • Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting • Execution of strategic... ► Artikel lesen | |
BEAM THERAPEUTICS | 21,270 | -3,54 % | Expert Ratings For Beam Therapeutics | ||
AGIOS | 30,800 | 0,00 % | Agios Pharmaceuticals, Inc.: Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights | - Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia - - Presented Positive Results from Phase 2 Portion of... ► Artikel lesen |